Navigation Links
In Key Opinion Leader Management, Quantity Does Not Equal Quality in Evaluating a Scientist's Real Importance
Date:9/30/2009

Using Social Network Analysis in Influence Mapping, Lnx Pharma Research Finds Pharmaceutical Companies May Be Ignoring Up To 50% of Key Scientific Leaders

Orange, CA (PRWEB) September 30, 2009 -- Lnx Pharma's new research results shatter current best practice for companies in pharmaceutical and biotechnology research who seek out "Key Opinion Leaders" (KOLs) among the scientific community to help advise research and development teams.

In drug development and pharmaceutical market research, companies seek out KOLs for many reasons, particularly in their pharmaceutical commercialization strategies. Until now, Key Opinion Leader Management focused primarily on those scientific leaders who are frequent publishers in high-visibility journals and academic papers, plus well-known speakers and educators.

Lnx Pharma, a research firm in Orange, CA that specializes in complex social network analysis for key opinion leader management and influence mapping, has found overwhelming evidence that pharmaceutical companies are missing consideration of a significant pool of truly valuable candidates that have influence in specific disease research worldwide - up to half of the most key influencers in a category.

"Our findings challenge the general notion that people who are productive authors are actually connected and meaningful to the community," says Philip Topham, General Manager. "Their ideas may be meaningful, but this shows that they don't always have the relationships with others in the community so their ideas may not be spread around as easily to peers and colleagues. If you're an isolated person, it's hard for ideas to flow. Conversely, there are people that companies might dismiss because there is not much evidence of their importance as measured by publication counts. But we find them highly connected in roles such as advisers and trusted colleagues, or subject matter experts to the community."

Lnx Pharma uses "social network analysis" to decipher the real relationships in the medical and pharmaceutical research communities. Applying their proprietary technology to the universe of people and publications, they found across multiple disease categories that 50% of potentially valuable key scientific leaders were actually not the most frequently published or cited scientists. That is to say, if pharmaceutical companies are only considering volume and popularity as a metric for evaluating key advisers, they are missing up to half of the people who may be truly of importance.

Analyzing over a dozen disease categories for clients who engage the company for custom research, Lnx Pharma consistently found many previously undervalued or unknown KOLs, but more importantly they uncovered critical information about how people work and organize around specific ideas and topics. Importance can't be reliably measured by a list using one or two ranking criteria. Lnx Pharma technology allows deciphering of the complex web of relationship in the ecosystem of human expert networks, identifying relative positions of individuals in the network, based on multiple highly relevant criteria. The results are critical not only for Key Opinion Leader management, but also for overall pharmaceutical marketing research.

"Many of our clients have completely adjusted their marketing strategy," says Topham. "It's incredibly expensive to put together an advisory board, and making mistakes about who to engage can be critical in the long run. Our system erases the biases of cronyism and publishing volume, as well as being more inclusive of global candidates. The result is a more balanced and truly relevant group of key opinion leaders."

The full results of Lnx Pharma's research will be presented at the CBI Research Conference "Defining Appropriate and Effective Interactions with Thought Leaders and Key Opinion Leaders (KOLs)", November 9-10. Companies and press interested in obtaining preview copies of the research may register for notification here: bit.ly/lnxpharmaform.

About Lnx Pharma
Lnx Pharma is a division of Lnx Research, LLC a privately held company based in Irvine, California, dedicated to leadership in the analysis of knowledge-creating communities. Lnx Research utilizes proprietary social network analysis methods and technologies to identify and understand "The Invisible College" of key opinion leaders in order to answer questions about knowledge communities for government and commercial clients in multiple industries. For white papers on this topic, or more specific information on Lnx Pharma, see lnxpharma.com.

###

Read the full story at http://www.prweb.com/releases/2009/09/prweb2958364.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
2. Alfacell Receives Going Concern Audit Opinion
3. Pharma Opinions Site Reviews the Breakthrough Drugs of Pharmaceutical Companies
4. Kuvan Receives Positive Opinion From CHMP for European Approval
5. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
6. FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
7. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
8. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
9. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
10. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
11. Three Expert Opinion Journals now Publishing Original Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
In Key Opinion Leader Management, Quantity Does Not Equal Quality in Evaluating a Scientist's Real Importance
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):